Practice Pearls

Potential clinical and financial causes for hesitation in the transition to subcutaneous dosing are addressed.

Experts provide perspective on how they prepare their staff for the transition to subcutaneous dosing.

The differences in subcutaneous formulation preparation and the corresponding impact on practice.

Experts consider the reasoning behind flat dosing of subcutaneous formulations, as well as its added benefit.

Key opinion leaders discuss the iStopMM study and the importance of early screening.

A discussion on the role of payers in the oral oncolytic dispensing process.

Expert panelists consider the future of the treatment of multiple myeloma, with oral oncolytics being the standard of therapy.

The panelists discuss the collaborative care plan in place for providing patients with the optimal treatment of multiple myeloma.

Key opinion leaders expand upon the difficulties that arise from the oral oncolytic dispensary system, including the inadequacy of community centers, time-consuming documentation, the appropriate utilization contingencies, and more.

A discussion on the role of specialty pharmacies in the oral oncolytic distribution process and the difficulties of patients who are geographically challenged.

Peter Salgo, MD, et al., consider the dispensing capabilities of pharmacies in addition to 7-days-off treatment plans.

Key opinion leaders discuss the policy of prior authorization and how it may affect the timely delivery of oral oncolytic therapy.